Rodent Model for Venous Stent Thrombosis Evaluated with Serial Ultrasound

In a rat model of IVC stent placement, rivaroxaban improved 1-week flow velocity (169 vs 98 mm/s, p<0.001) and 4-week patency (100% vs 67% control). High-frequency ultrasound tracked thrombosis/restenosis longitudinally.

• Study establishes a small-animal venous stent platform integrating longitudinal high-frequency ultrasound with histology for thrombosis and restenosis evaluation.
• Rivaroxaban-treated rats had the highest 4-week patency (100%) vs. clopidogrel (80%) and controls (67%).
• At 8 weeks, control animals exhibited the highest incidence of in-stent restenosis and thrombosis.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.